The present invention relates to the combination therapy of antibodies binding to human CSF-1R, characterized in binding to the (dimerization) domains D4 to D5 (SEQ ID No: 85) of the extracellular domain of human CSF-1R in combination with a chemotherapeutic agent, radiation, and/or cancer immunotherapy.본 발명은 특히 인간 CSF-1R에 결합하는 항체와 화학치료제, 방사선 및/또는 암 면역요법의 조합 요법에 관한 것이다.